In Search of a Disease-Modifying Agent for Parkinson’s Disease

Are Selective, Brain-Penetrant Inhibitors of LRRK2 an Answer?

In this white paper, we review a successful small molecule drug discovery project conducted by a team of scientists from Genentech and Charles River that spanned hit identification and lead optimization of a highly potent LRRK2 inhibitor.